AIBOTICS, INC.
For the period ended Mar 31, 2026. Filed Jun 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Jun 9, 2026
AIBTStored price and day change unavailable
Contents
Condensed Consolidated Balance Sheets as of March 31, 2026 (unaudited) and December 31,
| AIBIOTICS THERAPIES, INC | ||
|---|---|---|
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||
| AS OF MARCH 31, 2026 (UNAUDITED) AND DECEMBER 31, 2025 | ||
| March 31, | December 31, | |
| 2026 | 2025 | |
| (unaudited) | ||
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash | $288,858 | $255,940 |
| Prepaid expenses | 1,667 | 14,167 |
| Inventory | 40,525 | - |
| Total Current Assets | 331,050 | 270,107 |
| NON-CURRENT ASSETS: | ||
| Property and equipment, net | - | - |
| Intangible assets, net | 440,183 | 604,566 |
| TOTAL ASSETS | $771,233 | $874,673 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| CURRENT LIABILITIES: | ||
| Accounts payable and accrued expenses | $570,435 | $532,302 |
| Accrued interest | 879,000 | 807,000 |
| Accrued expenses – related party | 248,281 | 216,734 |
| Convertible note payable, net of debt discount | 1,193,018 | 1,118,269 |
| Notes payable – related party | 165,000 | 165,000 |
| Shares to be issued | 1,995,600 | 1,995,600 |
| TOTAL LIABILITIES | 5,051,334 | 4,834,905 |
| Commitments and contingencies (Note 9 – Commitments and Contingencies) | - | - |
| MEZZANINE EQUITY | ||
| Series B Preferred stock, $0.001 par value; 1,500,000 shares authorized at March 31, 2026 and December 31, 2025; 200,000 shares issued and outstanding as of March 31, 2026 and December 31, 2025; liquidation preference of $0 as of March 31, 2026 and December 31, 2025; 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025; liquidation preference of $0 as of March 31, 2026 and December 31, 2025 | 200 | 200 |
| STOCKHOLDERS’ DEFICIT | ||
| Preferred stock, 5,000,000 shares authorized: | ||
| Series A Preferred Stock, $0.001 par value, 0 shares authorized and outstanding at March 31, 2026 and December 31, 2025 | - | - |
| Common stock, $0.001 par value; 7,500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 539,367,487 and 486,895,359 shares issued and outstanding as of March 31, 2026, and December 31, 2025, respectively | 539,367 | 486,895 |
| Additional paid in capital | 8,623,444 | 8,577,680 |
| Accumulated deficit | (13,443,112) | (13,025,007) |
| TOTAL STOCKHOLDERS’ DEFICIT | (4,280,101) | (3,960,232) |
| TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT | $771,233 | $874,673 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.